|
1
|
Cuypers HT, Selten G, Quint W, Zijlstra M,
Maandag ER, Boelens W, van Wezenbeek P, Melief C and Berns A:
Murine leukemia virus-induced T-cell lymphomagenesis: Integration
of proviruses in a distinct chromosomal region. Cell. 37:141–150.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Eichmann A, Yuan L, Bréant C, Alitalo K
and Koskinen PJ: Developmental expression of pim kinases suggests
functions also outside of the hematopoietic system. Oncogene.
19:1215–1224. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nawijn MC, Alendar A and Berns A: For
better or for worse: The role of pim oncogenes in tumorigenesis.
Nat Rev Cancer. 11:23–34. 2011. View
Article : Google Scholar
|
|
4
|
Jinesh GG, Mokkapati S, Zhu K and Morales
EE: Pim kinase isoforms: Devils defending cancer cells from
therapeutic and immune attacks. Apoptosis. 21:1203–1213. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yan B, Zemskova M, Holder S, Chin V, Kraft
A, Koskinen PJ and Lilly M: The PIM-2 kinase phosphorylates BAD on
serine 112 and reverses BAD-induced cell death. J Biol Chem.
278:45358–45367. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ren K, Gou X, Xiao M, He W and Kang J:
Pim-2 cooperates with downstream factor XIAP to inhibit apoptosis
and intensify malignant grade in prostate cancer. Pathol Oncol Res.
25:341–348. 2019. View Article : Google Scholar
|
|
7
|
Nair JR, Caserta J, Belko K, Howell T,
Fetterly G, Baldino C and Lee KP: Novel inhibition of PIM2 kinase
has significant anti-tumor efficacy in multiple myeloma. Leukemia.
31:1715–1726. 2017. View Article : Google Scholar :
|
|
8
|
Hideshima T, Nakamura N, Chauhan D and
Anderson KC: Biologic sequelae of interleukin-6 induced PI3-K/Akt
signaling in multiple myeloma. Oncogene. 20:5991–6000. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fox CJ, Hammerman PS, Cinalli RM, Master
SR, Chodosh LA and Thompson CB: The serine/threonine kinase Pim-2
is a transcriptionally regulated apoptotic inhibitor. Genes Dev.
17:1841–1854. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cervantes-Gomez F, Stellrecht CM, Ayres
ML, Keating MJ, Wierda WG and Gandhi V: PIM kinase inhibitor,
AZD1208, inhibits protein translation and induces autophagy in
primary chronic lymphocytic leukemia cells. Oncotarget.
10:2793–2809. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen LS, Yang JY, Liang H, Cortes JE and
Gandhi V: Protein profiling identifies mTOR pathway modulation and
cytostatic effects of pim kinase inhibitor, AZD1208, in acute
myeloid leukemia. Leuk Lymphoma. 57:2863–2873. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen LS, Redkar S, Taverna P, Cortes JE
and Gandhi V: Mechanisms of cytotoxicity to pim kinase inhibitor,
SGI-1776, in acute myeloid leukemia. Blood. 118:693–702. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang Q, Chen LS, Neelapu SS, Miranda RN,
Medeiros LJ and Gandhi V: Transcription and translation are primary
targets of pim kinase inhibitor SGI-1776 in mantle cell lymphoma.
Blood. 120:3491–3500. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yang Q, Chen LS, Neelapu SS and Gandhi V:
Combination of pim kinase inhibitor SGI-1776 and bendamustine in
B-cell lymphoma. Clin Lymphoma Myeloma Leuk. 13(Suppl 2):
S355–S362. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cervantes-Gomez F, Chen LS, Orlowski RZ
and Gandhi V: Biological effects of the pim kinase inhibitor,
SGI-1776, in multiple myeloma. Clin Lymphoma Myeloma Leuk. 13(Suppl
2): S317–S329. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cortes J, Tamura K, DeAngelo DJ, de Bono
J, Lorente D, Minden M, Uy GL, Kantarjian H, Chen LS, Gandhi V, et
al: Phase I studies of AZD1208, a proviral integration moloney
virus kinase inhibitor in solid and haematological cancers. Br J
Cancer. 118:1425–1433. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Uddin N, Kim RK, Yoo KC, Kim YH, Cui YH,
Kim IG, Suh Y and Lee SJ: Persistent activation of STAT3 by
PIM2-driven positive feedback loop for epithelial-mesenchymal
transition in breast cancer. Cancer Sci. 106:718–725. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Han X, Ren C, Yang T, Qiao P, Wang L,
Jiang A, Meng Y, Liu Z, Du Y and Yu Z: Negative regulation of
AMPKalpha1 by PIM2 promotes aerobic glycolysis and tumorigenesis in
endometrial cancer. Oncogene. 38:6537–6549. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6:112013. View Article : Google Scholar
|
|
21
|
Barretina J, Caponigro G, Stransky N,
Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV,
Sonkin D, et al: The cancer cell line encyclopedia enables
predictive modelling of anticancer drug sensitivity. Nature.
483:603–607. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ghandi M, Huang FW, Jané-Valbuena J,
Kryukov GV, Lo CC, McDonald ER III, Barretina J, Gelfand ET,
Bielski CM, Li H, et al: Next-generation characterization of the
cancer cell line encyclopedia. Nature. 569:503–508. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Baldino CM, Caserta J, Lee CS, Nicewonger
R, Flanders Y and Dumas S: Aminopyrimidine kinase inhibitors. Jasco
Pharmaceuticals LLC; United States: 2013
|
|
24
|
Flanders Y, Dumas S, Caserta J, Nicewonger
R, Baldino M, Lee CS and Badlino CM: A versatile synthesis of novel
pan-PIM kinase inhibitors with initial SAR study. Tetrahedron Lett.
56:3186–3190. 2015. View Article : Google Scholar
|
|
25
|
Zhang X, Song M, Kundu JK, Lee MH and Liu
ZZ: PIM kinase as an executional target in cancer. J Cancer Prev.
23:109–116. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dakin LA, Block MH, Chen H, Code E,
Dowling JE, Feng X, Ferguson AD, Green I, Hird AW, Howard T, et al:
Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as
potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3
protein kinases. Bioorg Med Chem Lett. 22:4599–4604. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tamburini J, Green AS, Bardet V, Chapuis
N, Park S, Willems L, Uzunov M, Ifrah N, Dreyfus F, Lacombe C, et
al: Protein synthesis is resistant to rapamycin and constitutes a
promising therapeutic target in acute myeloid leukemia. Blood.
114:1618–1627. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Katsuta E, DeMasi SC, Terracina KP,
Spiegel S, Phan GQ, Bear HD and Takabe K: Modified breast cancer
model for preclinical immunotherapy studies. J Surg Res.
204:467–474. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Katsuta E, Oshi M, Rashid OM and Takabe K:
Generating a murine orthotopic metastatic breast cancer model and
performing murine radical mastectomy. J Vis Exp. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Katsuta E, Rashid OM and Takabe K: Murine
breast cancer mastectomy model that predicts patient outcomes for
drug development. J Surg Res. 219:310–318. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Katsuta E, Rashid OM and Takabe K:
Clinical relevance of tumor microenvironment: immune cells,
vessels, and mouse models. Human Cell. 33:930–937. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Curtis C, Shah SP, Chin SF, Turashvili G,
Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, et
al: The genomic and transcriptomic architecture of 2,000 breast
tumours reveals novel subgroups. Nature. 486:346–352. 2012.
View Article : Google Scholar : PubMed/NCBI
|
